Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery

Obesity Surgery

Volumn 16, Issue 12, 2006, Pages 1645-1655

  Rocha, Ana Thereza ^a,c   De Vasconcellos, Ângela G ^a   Da Luz Neto, Epitácio R ^a   Araújo, Danilo M A ^a   Alves, Erivaldo S ^b   Lopes, Antônio Alberto ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Hospital Salvador   (Brazil)

^c NONE   (Brazil)

Author keywords

Bariatric surgery; Embolism and thrombosis; Heparin; Morbid obesity; Obesity; Prevention and control; Risk factors

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; BARIATRIC SURGERY; DRUG EFFICACY; DRUG SAFETY; HOSPITALIZATION; HUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL RISK; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

BARIATRIC SURGERY; FIBRINOLYTIC AGENTS; HUMANS; OBESITY, MORBID; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 33845924755     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1381/096089206779319383     Document Type: Review

References (42)

1. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93: 259-62.
2. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-31.
3. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001; 21: 218-34.
4. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
5. Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
6. Alikhan R, Cohen AT, Combe S et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963-8.
7. Grady D, Wenger NK, Herrington D et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-96.
8. Cogo A, Bernardi E, Prandoni P et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med 1994; 154: 164-8.
9. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-15.
10. Blaszyk H, Wollan PC, Witkiewicz AK et al. Death from pulmonary thromboembolism in severe obesity: lack of association with established genetic and clinical risk factors. Virchows Arch 1999; 434: 529-32.
11. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-20.
12. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-8.
13. Tsai AW, Cushman M, Rosamond WD et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-9.
14. Hansson PO, Eriksson H, Welin L et al. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "the study of men born in 1913". Arch Intern Med 1999; 159: 1886-90.
15. Goldhaber SZ, Grodstein F, Stampfer MJ et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 642-5.
16. Alikhan R, Cohen AT, Combe S et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341-6.
17. Leizorovicz A, Cohen AT, Turpie AG et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-9.
18. Kucher N, Leizorovicz A, Vaitkus PT et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005; 165: 341-5.
19. Eriksson S, Backman L, Ljungstrom KG. The incidence of clinical postoperative thrombosis after gastric surgery for obesity during 16 years. Obes Surg 1997; 7: 332-5.
20. Bajardi G, Ricevuto G, Mastrandrea G et al. [Postoperative venous thromboembolism in bariatric surgery]. Minerva Chir 1993; 48: 539-42.
21. Westling A, Bergqvist D, Bostrom A et al. Incidence of deep venous thrombosis in patients undergoing obesity surgery. World J Surg 2002; 26: 470-3.
22. Printen KJ, Miller EV, Mason EE et al. Venous thromboembolism in the morbidly obese. Surg Gynecol Obstet 1978; 147: 63-4.
23. Podnos YD, Jimenez JC, Wilson SE et al. Complications after laparoscopic gastric bypass: a review of 3464 cases. Arch Surg 2003; 138: 957-61.
24. Cotter SA, Cantrell W, Fisher B et al. Efficacy of venous thromboembolism prophylaxis in morbidly obese patients undergoing gastric bypass surgery. Obes Surg 2005; 15: 1316-20.
25. Omalu BI, Luckasevic T, Shakir AM et al. Postbariatric surgery deaths, which fall under the jurisdiction of the coroner. Am J Forensic Med Pathol 2004; 25: 237-42.
26. Melinek J, Livingston E, Cortina G et al. Autopsy findings following gastric bypass surgery for morbid obesity. Arch Pathol Lab Med 2002; 126: 1091-5.
27. Borow M, Goldson H. Postoperative venous thrombosis. Evaluation of five methods of treatment. Am J Surg 1981; 141: 245-51.
28. Gonzalez QH, Tishler DS, Plata-Munoz JJ et al. Incidence of clinically evident deep venous thrombosis after laparoscopic Roux-en-Y gastric bypass. Surg Endosc 2004; 18: 1082-4.
29. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002; 12: 19-24.
30. Kalfarentzos F, Stavropoulou F, Yarmenitis S et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg 2001; 11: 670-6.
31. Miller MT, Rovito PF. An approach to venous thromboembolism prophylaxis in laparoscopic Roux-en-Y gastric bypass surgery. Obes Surg 2004; 14: 731-7.
32. Shepherd MF, Rosborough TK, Schwartz ML. Heparin thromboprophylaxis in gastric bypass surgery. Obes Surg 2003; 13: 249-53.
33. Quebbemann B, Akhondzadeh M, Dallal R. Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes Surg 2005; 15: 1221-4.
34. Shepherd F, Rosborough TK, Schwartz ML. Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery. Obes Surg 2004; 14: 601-5.
35. Kimmerly WS, Sellers KD, Deitcher SR. Graduate surgical trainee attitudes toward postoperative thromboprophylaxis. South Med J 1999; 92: 790-4.
36. Goldhaber SZ, Savage DD, Garrison RJ et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983; 74: 1023-8.
37. Thompson WR, Amaral JF, Caldwell MD et al. Complications and weight loss in 150 consecutive gastric exclusion patients. Critical review. Am J Surg 1983; 146: 602-12.
38. Mason EE, Renquist KE, Jiang D. Perioperative risks and safety of surgery for severe obesity. Am J Clin Nutr 1992; 55 (Suppl): 573S-576S.
39. Sugerman HJ, Sugerman EL, Wolfe L et al. Risks and benefits of gastric bypass in morbidly obese patients with severe venous stasis disease. Ann Surg 2001; 234: 41-6.
40. Sapala JA, Wood MH, Schuhknecht MP et al. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obes Surg 2003; 13: 819-25.
41. Carbajo M, Garcia-Caballero M, Toledano M et al. One-anastomosis gastric bypass by laparoscopy: results of the first 209 patients. Obes Surg 2005; 15: 398-404.
42. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 2005; 15: 1368-74.